Get started
BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1

BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

BMY chart


Full chart

Key facts today


Bristol-Myers Squibb's Cobenfy trial for schizophrenia failed to meet its main goal, showing only a 2-point score drop. Shares fell nearly 6% in after-hours trading.
Cantor Fitzgerald has initiated coverage of Bristol-Myers Squibb (BMY) with a 'Neutral' rating.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪108.71 T‬ ARS
Dividend yield (indicated)
4.84%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1,200 ARS
Net income (FY)
‪−8.19 T‬ ARS
Revenue (FY)
‪44.23 T‬ ARS
Shares float
—
Beta (1Y)
−0.020

About Bristol-Myers Squibb Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Christopher S. Boerner
Website
bms.com
Headquarters
Princeton
Founded
1933
ISIN
ARDEUT112877
FIGI
BBG000L7BMZ1
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BMY news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BMY highest yielding bonds


US110122DS4
BRIST.MYERS 20/50
Yield to maturity
7.69%
Maturity date
Nov 13, 2050
C
BMY4275603
Celgene Corporation 5.0% 15-AUG-2045
Yield to maturity
7.51%
Maturity date
Aug 15, 2045
US110122DR6
BRIST.MYERS 20/40
Yield to maturity
7.00%
Maturity date
Nov 13, 2040
US110122DX3
BRIST.MYERS 22/62
Yield to maturity
6.96%
Maturity date
Mar 15, 2062
US110122DW5
BRIST.MYERS 22/52
Yield to maturity
6.92%
Maturity date
Mar 15, 2052
BMY3883364
Bristol-Myers Squibb Company 3.25% 01-AUG-2042
Yield to maturity
6.79%
Maturity date
Aug 1, 2042
C
BMY4560589
Celgene Corporation 4.35% 15-NOV-2047
Yield to maturity
6.70%
Maturity date
Nov 15, 2047
BMY5009254
Bristol-Myers Squibb Company 4.25% 26-OCT-2049
Yield to maturity
6.66%
Maturity date
Oct 26, 2049
US110122DV7
BRIST.MYERS 22/42
Yield to maturity
6.61%
Maturity date
Mar 15, 2042
C
BMY3685700
Celgene Corporation 5.7% 15-OCT-2040
Yield to maturity
6.59%
Maturity date
Oct 15, 2040
BMY5009251
Bristol-Myers Squibb Company 4.35% 15-NOV-2047
Yield to maturity
6.56%
Maturity date
Nov 15, 2047

See all BMY bonds 

Sparks


Curated watchlists where BMY is featured.

See all sparks 


Check out other big names from the same industry as BMY.